Cheng Shen | Cardiac Surgery | Best Researcher Award

Prof. Dr. Cheng Shen | Cardiac Surgery | Best Researcher Award

West China Hospital | China

Author Profile: 

Scopus

Orcid

📘 EARLY ACADEMIC PURSUITS 

Cheng Shen began his academic journey at Kunming Medical University, earning his Bachelor of Medicine in Clinical Medicine in 2011. His passion for clinical excellence and research led him to the West China School of Medicine, Sichuan University, where he pursued a Ph.D. in Thoracic Surgery while simultaneously working as a Resident Doctor and Research Assistant from 2011 to 2017. During this period, he honed his clinical and research acumen, laying a strong foundation for his future contributions to oncology and thoracic surgery.

🩺 PROFESSIONAL ENDEAVORS

Dr. Cheng Shen currently serves as an Attending Physician in the Department of Thoracic Surgery at West China Hospital, Sichuan University. His international academic exposure includes his time as a Visiting Scholar at Yale University (2015–2016) in the Department of Molecular Biophysics and Biochemistry, where he advanced his expertise in molecular mechanisms of DNA repair. This blend of clinical practice and laboratory precision has equipped him to lead cutting-edge investigations in thoracic oncology.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON CARDIAC SURGERY

Dr. Shen’s research spans several high-impact domains, including:

  • Targeted Gene Therapy and Immunotherapy

  • Molecular Mechanisms of Cancer Invasion and Metastasis

  • Cell and Tissue Engineering

  • Stem Cell Function and Differentiation

His research during his Yale tenure focused on the mechanism of homology-directed DNA repair, using yeast and human models. He also explored genomic instability in primary lung cancers and conducted studies on cancer-associated fibroblasts in lung adenocarcinoma.

🌐 IMPACT AND INFLUENCE 

Cheng Shen has contributed significantly to the understanding of tumor biology, particularly in thoracic malignancies. His ability to translate complex molecular biology into practical clinical insights makes him a crucial figure in personalized cancer therapy. He has also designed and led several small clinical trials, emphasizing his commitment to bridging the bench-to-bedside gap.

🏅 ACADEMIC CITES AND COLLABORATIONS

While specific citation counts are not provided, his training at Yale University, multiple national-level scholarships, and leadership in clinical trials reflect a robust academic profile. His research work is likely referenced in the fields of genomic instability, lung cancer, and DNA repair mechanisms.

🚀 LEGACY AND FUTURE CONTRIBUTIONS

Dr. Cheng Shen’s future appears poised for further breakthroughs in thoracic cancer treatment and regenerative medicine. As a physician-scientist with deep laboratory roots and clinical experience, he is uniquely positioned to drive innovation in cancer therapy, particularly with emerging gene and cell-based interventions. His trajectory indicates continued leadership in integrative and translational medical research.

🏆 OTHER IMPORTANT AREAS OF EXCELLENCE 

LANGUAGE PROFICIENCY:

  • Advanced in English, having cleared PETS-3, PETS-4, CET-4, and CET-6.

LAB PROFICIENCY:

  • Expertise in PCR, Western Blot, ELISA, Cell Culture, and Signaling Pathway Inhibition.

  • Strong in Animal Models and Transwell Cell Migration assays.

HONORS & SCHOLARSHIPS:

  • State Scholarship Fund (CSC) (2015–2017)

  • National Graduate Scholarships (2012–2014)

  • Full Scholarship from Sichuan University (2011–2016)

  • Multiple Merit Scholarships during undergraduate studies

NOTABLE PUBLICATIONS

"Accuracy of Large Language Models for Literature Screening in Thoracic Surgery: Diagnostic Study"

Authors: ZY Dai, FQ Wang, C Shen, YL Ji, ZY Li, Y Wang, Q Pu
Journal: Journal of Medical Internet Research
Year: 2025

"A combined subsegmentectomy of right S9 + 10b with single direction thoracoscopic surgery"

Authors: C Shen, C Liu
Journal: Journal of Cardiothoracic Surgery
Year: 2024

"Robot-assisted thoracic surgery versus video-assisted thoracic surgery for treatment of patients with thymoma: A systematic review and meta-analysis"

Authors: Shen C, Li J, Li J, Che G
Journal: Thoracic Cancer
Year: 2022

Mengchao Wei | Venous thromboembolism | Best Researcher Award

Dr. Mengchao Wei | Venous thromboembolism | Best Researcher Award

Dr. Mengchao Wei, Peking Union Medical College Hospital, China

Dr. Mengchao Wei is a physician at Peking Union Medical College Hospital, China, specializing in Urology. He graduated with a Doctor’s degree from Sun Yat-sen University in 2019. Since joining PUMCH in 2021, Dr. Wei has focused on optimizing perioperative management for urologic surgeries. He developed a predictive model for venous thromboembolism risk post-surgery, now integrated into clinical practice. Dr. Wei has published 10 journal articles in SCI and Scopus indexed journals. His research aims to improve patient safety and surgical outcomes, making significant contributions to the field of urologic surgery.

Author Profile

Orcid Profile

📚Early Academic Pursuits: 

Dr. Mengchao Wei graduated with a Doctor’s degree from Sun Yat-sen University in 2019. His academic journey laid the foundation for his current work, particularly in the field of Urology, where he became deeply involved in understanding the nuances of perioperative management in urologic surgeries. His comprehensive training and early research set him on a path to clinical excellence and innovation.

⚕️Professional Endeavors and Contributions: 

Since 2021, Dr. Wei has been practicing as a Physician at Peking Union Medical College Hospital, where his focus lies in the optimization of perioperative management in urologic surgeries. His clinical work has had a direct impact on improving patient care and the efficiency of surgical outcomes. Dr. Wei’s contributions include the development of a predictive model for venous thromboembolism risk following urologic surgeries, which has been implemented in real-world clinical practice to enhance patient safety.

🔬Research Focus and Innovations on Venous thromboembolism:

Dr. Wei’s research centers on perioperative management within urology, particularly concerning venous thromboembolism (VTE) risk. His predictive model for VTE risk, now utilized in clinical settings, showcases his ability to translate research into tangible, life-saving outcomes. While his citation index stands at 10, his work continues to gain attention in the medical community. He has published 10 journals in esteemed databases such as SCI and Scopus, reinforcing his status as a respected figure in urologic research.

🌍Impact and Influence: 

Dr. Wei’s contributions have not only benefited his hospital but also shaped the way urologic surgeries are managed perioperatively. By providing a tool that enhances clinical decision-making, he directly improves surgical outcomes, patient safety, and overall healthcare efficiency. His work has influenced peers, setting a new standard in the field of urology.

📑Academic Citations:

Dr. Wei has an impressive citation index of 10, a reflection of the growing recognition of his work and the clinical value it brings. His research continues to receive acknowledgment in relevant medical journals, contributing to the advancement of perioperative care in urology.

🚀Legacy and Future Contributions: 

Dr. Wei’s research and innovations indicate a promising future in the field of urology. He is committed to enhancing perioperative management for urologic surgeries and advancing clinical practices. Moving forward, his aim is to refine predictive models and further contribute to patient safety and surgical excellence.

🌟Conclusion:

Dr. Mengchao Wei’s work at Peking Union Medical College Hospital has made a significant impact on perioperative management in urologic surgeries. His predictive model for venous thromboembolism risk has been successfully integrated into clinical practice, improving patient outcomes and safety. With 10 journal publications in SCI and Scopus indexed journals, Dr. Wei is recognized as a dedicated and innovative physician. His contributions are shaping the future of urologic surgery. As he continues to push the boundaries of medical research, his work promises to enhance the quality of care and patient safety worldwide.

Top Notable Publications 

A nomogram predicting the risk of venous thromboembolism in patients following urologic surgeries

Authors: Mengchao Wei

Journal: Scientific Reports

Year: 2025

The role of antimicrobial prophylaxis in laparoscopic nephrectomy for renal cell carcinoma

Authors: Mengchao Wei

Journal: BMC Urology

Year: 2024

Comparison of AirSeal versus conventional insufflation system for retroperitoneal robot-assisted laparoscopic partial nephrectomy: a randomized controlled trial

Authors: Mengchao Wei

Journal: World Journal of Urology

Year: 2024

Surgery or external beam radiation for solitary small hepatocellular carcinoma

Authors: Mengchao Wei

Journal: Journal of Cancer Research and Therapeutics

Year: 2023

Adjuvant Sorafenib Following Radiofrequency Ablation for Early-Stage Recurrent Hepatocellular Carcinoma With Microvascular Invasion at the Initial Hepatectomy

Authors: Mengchao Wei

Journal: Frontiers in Oncology

Year: 2022

Role of Preoperational Imaging Traits for Guiding Treatment in Single ≤ 5 cm Hepatocellular Carcinoma

Authors: Mengchao Wei

Journal: Annals of Surgical Oncology

Year: 2022

The Combination of Radiation Therapy and Immunotherapy Is Effective and Well-Tolerated for Unresectable Biliary Tract Cancer

Authors: Mengchao Wei

Journal: International Journal of Radiation Oncology, Biology, Physics

Year: 2022

Prognostic Role of Time to Surgery in Hepatocellular Carcinoma at Barcelona Clinic Liver Cancer Stage 0-A

Authors: Mengchao Wei

Journal: Annals of Surgical Oncology

Year: 2020

Radiofrequency ablation plus nucleotide analogues for hepatitis B virus-related hepatocellular carcinoma: a cost-effectiveness analysis

Authors: Mengchao Wei

Journal: American Journal of Translational Research

Year: 2018

Sorafenib versus Transarterial Chemoembolization for Advanced-Stage Hepatocellular Carcinoma: A Cost-Effectiveness Analysis

Authors: Mengchao Wei

Journal: BMC Cancer

Year: 2018